We live in the age of optimisation. Constantly asking questions like how can we be more efficient? How can we streamline processes? How can we enhance ourselves with the resources available? The pharmaceutical scene is no different, seeking to optimise drugs in any way possible to produce better patient outcomes. Biopharmaceutical company Starpharma (ASX: SPL)
Read MoreOne of the world’s most respected surgeons in the field of burns and trauma recovery will lead world-first clinical trials aiming to stop scars forming, particularly after burn injuries, utilising the latest discovery by biopharmaceuticals company Pharmaxis (ASX: PXS). The discovery, known as PXS-6302 has shown promising pre‐clinical results in inhibiting the enzymes that play
Read MoreWith China having lost more than 100 million pigs due to the recent outbreak of African swine fever in the mainland, attention has been thrust upon preventative measures, leading a Chinese Group to engage chemical company Zoono (ASX: ZNO) for a 10-year distribution arrangement. The Chinese Group will use the Zoono China brand to sell
Read MoreAustralian biopharmaceuticals developer Neuren Pharmaceuticals (ASX: NEU) has been granted a patent from the European Patent Office covering NNZ-2591, a world-first drug being developed to treat three neurodevelopmental disorders which affect children, and are currently incurable. The granting of the new patent is the third jurisdiction to do so for Neuren with the same application
Read MoreBiopharmaceuticals manufacturer MGC Pharmaceuticals (ASX: MXC) has seen significant uptake of its cannabinoid medications with prescriptions across Australia and the United Kingdom doubling to 800 patients through the month of October. The update comes as more medical practitioners prescribe phytocannabinoid-derived medications CannEpil®, which targets drug-resistant epilepsy, and MXP100 which is recommended for neurological disorders, inflammation
Read MoreThe content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.